RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 3, 2006--Talecris Biotherapeutics today announced the launch of Talents, the Talecris New Trials Support program, an initiative supporting investigator-initiated trials conceived by researchers and clinicians with an interest in intravenous immunoglobulin (IGIV) therapies. Each year, Talecris will pledge $1 million to fund basic science and clinical research projects in various fields, including immunology, hematology, and neurology. Talecris produces and markets Gamunex®, a leading IGIV therapy, and the Talents program is another example of its ongoing commitment to the IGIV community.
